RegeneRx Biopharmaceuticals Inc logo

RGRX - RegeneRx Biopharmaceuticals Inc News Story

$0.24 0.0  4.2%

Last Trade - 22/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £22.0m
Enterprise Value £22.4m
Revenue £55.1k
Position in Universe 5944th / 6852

BRIEF-RegeneRx Issues Advisory On Dry Eye Trial Amid COVID-19 Virus

Wed 18th March, 2020 2:17pm
March 18 (Reuters) - RegeneRx Biopharmaceuticals Inc
 RGRX.PK :
    * REGENERX ISSUES ADVISORY ON DRY EYE TRIAL AMID COVID-19
VIRUS
    * REGENERX - GTREEBNT TEAM MET CONTRACT RESEARCH
ORGANIZATION
MANAGING ARISE-3 TRIAL, TO DISCUSS CHANGES IN ENROLLMENT
ASSOCIATED WITH COVID-19 VIRUS
    * REGENERX - GTREEBNT,CRO CONTINUE WORKING TO ACHIEVE GOAL
OF
COMPLETING ARISE-3 TRIAL, OBTAINING RESULTS WITHIN INITIAL
PLANNED SCHEDULE
    * REGENERX BIOPHARMACEUTICALS - TO DATE, THERE HAS BEEN
LITTLE TO
NO EFFECT ON ENROLLMENT & CONTINUED TREATMENT OF DRY EYE
PATIENTS ENTERED INTO TRIAL

Source text for Eikon:  ID:nPn2b7rFFa 
Further company coverage:  RGRX.PK 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.